- Home
- RIVN vs INCY Comparison
RIVN vs INCY Comparison
Compare RIVN & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIVN
- INCY
- Stock Information
- Founded
- RIVN 2009
- INCY 1991
- Country
- RIVN United States
- INCY United States
- Employees
- RIVN N/A
- INCY N/A
- Industry
- RIVN Auto Manufacturing
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- RIVN Consumer Discretionary
- INCY Health Care
- Exchange
- RIVN Nasdaq
- INCY Nasdaq
- Market Cap
- RIVN 13.0B
- INCY 13.4B
- IPO Year
- RIVN 2021
- INCY 1993
- Fundamental
- Price
- RIVN $12.29
- INCY $59.98
- Analyst Decision
- RIVN Hold
- INCY Hold
- Analyst Count
- RIVN 21
- INCY 20
- Target Price
- RIVN $14.10
- INCY $74.00
- AVG Volume (30 Days)
- RIVN 28.7M
- INCY 2.2M
- Earning Date
- RIVN 05-06-2025
- INCY 04-29-2025
- Dividend Yield
- RIVN N/A
- INCY N/A
- EPS Growth
- RIVN N/A
- INCY N/A
- EPS
- RIVN N/A
- INCY 0.15
- Revenue
- RIVN $4,970,000,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- RIVN $10.80
- INCY $12.23
- Revenue Next Year
- RIVN $36.10
- INCY $8.89
- P/E Ratio
- RIVN N/A
- INCY $359.58
- Revenue Growth
- RIVN 12.09
- INCY 14.76
- 52 Week Low
- RIVN $8.26
- INCY $50.35
- 52 Week High
- RIVN $18.86
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- RIVN 55.06
- INCY 30.18
- Support Level
- RIVN $10.72
- INCY $60.24
- Resistance Level
- RIVN $13.30
- INCY $63.31
- Average True Range (ATR)
- RIVN 0.62
- INCY 2.02
- MACD
- RIVN 0.25
- INCY -0.32
- Stochastic Oscillator
- RIVN 68.44
- INCY 16.22
About RIVN Rivian Automotive Inc.
Rivian Automotive Inc designs, develops, and manufactures category-defining electric vehicles and accessories. In the consumer market, the company launched the R1 platform with the first generation of consumer vehicles: the R1T, a two-row, five-passenger pickup truck, and the R1S, a three-row, seven-passenger sport utility vehicle (SUV).
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.